In this issue of JAMA Oncology, Diefenhardt and colleagues1 report a post hoc analysis of the previously published German CAO/ARO/AIO-04 trial2 and found that the ability of patients with rectal cancer to complete planned neoadjuvant (but not adjuvant) therapy was associated with improved disease-free survival. The authors concluded “the findings emphasize the need for appropriate trial design with optimized nCRT [neoadjuvant chemoradiotherapy] dose and schedule and supportive strategies to facilitate good adherence and precision delivery, especially for intensified nCRT.”1 Few would dispute this broad point, but the greater challenge lies in aligning their recommendations with current paradigms of rectal cancer treatment, which have evolved dynamically since the CAO/ARO/AIO-04 study.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Madoff RD, Lou E. Locally Advanced Rectal Cancer—Precision Therapy in a Time of Moving Targets and Competing Goals. JAMA Oncol. Published online July 09, 2020. doi:10.1001/jamaoncol.2020.2208
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: